Radical immune 'Reset' tested as potential lifeline for Tough-to-Treat lupus
Disease control
Not yet recruiting
This early-stage study is testing a new type of cell therapy called ICG318 for people with severe, hard-to-treat systemic lupus erythematosus (SLE), including lupus affecting the kidneys. The therapy involves modifying a patient's own immune cells (CAR-T cells) to target and remo…
Phase: PHASE1, PHASE2 • Sponsor: iCell Gene Therapeutics • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC